Bayer Korea R&D

Bayer is committed to contributing to the development of the pharmaceutical industry in Korea through a variety of studies including early clinical studies, while expanding business areas by encouraging active investment in the research and development sector in South Korea. Bayer has recently been participating in more global clinical trials, and as of 2010 is taking part in 28 global clinical trials, occupying a higher share with 56 percent of the total global clinical trials. Furthermore, in contrast to the majority of other global pharmaceutical companies in South Korea that are closing their plants or reducing their size, Bayer is further bolstering its investment activities in active research and development such as the expansion of contrast media factories.

Bayer Korea was granted permission to conduct phase 0 clinical trials for the first time in Korea. On March 30, 2010, Bayer Korea was granted permission for conduct of phase 0 clinical trials (Exploratory or Microdose study) from the Korea Food and Drug Administration. Phase 0 clinical trials are a form of clinical trials (Exploratory or Microdose study) led by pharmaceutical companies to study pharmacodynamic and pharmacokinetic properties of a drug in the human body with subclinical doses before a clinical trial. Phase 0 trials are a small scale clinical trial designed to check the drug’s mechanism of action prior to patient trials.

On September 10, 2010, Bayer Korea held a building dedication ceremony to celebrate the extension of the Quality Control Lab at the Bayer HealthCare Anseong Plant. This extension was completed by adding an area of 682 square meters over the period of six months with the goal of developing a global level quality control laboratory. Since its completion in 1994, the Anseong Plant has steadily invested in the manufacturing of products with the best quality on the basis of the best technological capabilities.

The PATH (Program for the Advancement of Therapy in Hepatocellular Carcinoma) program, which is sponsored by Bayer, recognizes key hospitals that stand out in the liver cancer field every year by providing doctors selected from countries all over the world with an opportunity to acquire the newest technology for the liver cancer field.